Fibrocell to Present at Upcoming Industry and Investor Conferences
September 26 2018 - 8:00AM
Fibrocell Science, Inc., (NASDAQ: FCSC), a gene therapy company
focused on transformational autologous cell-based therapies for
skin and connective tissue diseases, today announced that John
Maslowski, President and Chief Executive Officer, will present at
these industry and investor conferences in October 2018:
- Cell & Gene Meeting on the Mesa on
Wednesday, October 3rd at 3:00 p.m. PDT in La Jolla, CA
- Chardan 2nd Annual Genetic Medicines
Conference on Tuesday, October 9th at 7:30 a.m. EDT
in New York City
A live webcast of each Fibrocell presentation
will be available under the investor relations section of the
Company’s website at www.fibrocell.com/investors/events, and will
be archived for 30 days following each event.
About Fibrocell
Fibrocell is an autologous cell and gene therapy
company translating personalized biologics into medical
breakthroughs for diseases affecting the skin and connective
tissue. Fibrocell’s most advanced product candidate, FCX-007,
is the subject of a Phase 1/2 clinical trial for the treatment of
recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is
also developing FCX-013, the Company’s clinical stage candidate for
the treatment of moderate to severe localized
scleroderma. Fibrocell’s gene therapy portfolio is being
developed in collaboration with Precigen, Inc., a wholly owned
subsidiary of Intrexon Corporation (NASDAQ: XON), a leader in
synthetic biology. For more information, visit
www.fibrocell.com or follow Fibrocell on Twitter at @Fibrocell.
Trademarks
Fibrocell®, the Fibrocell logo, and Fibrocell
Science® are trademarks of Fibrocell Science, Inc. and/or its
affiliates. All other names may be trademarks of their
respective owners.
Investor Relations Contact: Karen
Casey484.713.6133 kcasey@fibrocell.com
Fibrocell Science (NASDAQ:FCSC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fibrocell Science (NASDAQ:FCSC)
Historical Stock Chart
From Apr 2023 to Apr 2024